Talking about those legal threats

The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained why the threat of (baseless) lawsuits from pharma companies can keep some pharmacists from talking about it.

Bonus: Both Eli Lilly and Novo Nordisk admitted to threatening compounders even without legal basis.

One of the better articles we've seen lately comes from USA Today, explaining what is likely to...

Getting away from GLP-1s, Pharmaceutical Executive features CEO Scott Brunner and Chief Advocacy...

UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s...

Talking about those legal threats

Related posts

USA Today’s balanced article on the future of GLP-1s

PharmExec features APC execs talking about the compounding process

The Brits could have done better